{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:06:45Z","timestamp":1788883605656,"version":"build-2803163510"},"reference-count":187,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omtn.2026.103060","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:55:42Z","timestamp":1786690542000},"page":"103060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation macrophage engineering in cancer therapy: From TAM reprogramming to CAR-macrophages"],"prefix":"10.1016","volume":"37","author":[{"given":"Olga","family":"Nilova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-1103","authenticated-orcid":false,"given":"Anna","family":"Zajakina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.103060_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib3","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103060_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage\u2013mediated resistance pathway in anti\u2013PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib5","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.7150\/jca.25155","article-title":"Stromal Infiltration of Tumor-Associated Macrophages Conferring Poor Prognosis of Patients with Basal-Like Breast Carcinoma","volume":"9","author":"Yang","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1677\/ERC-08-0036","article-title":"Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer","volume":"15","author":"Ryder","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib7","first-page":"5871","article-title":"Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells","volume":"18","author":"Ke","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omtn.2026.103060_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2026.103060_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","article-title":"Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A\/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity","volume":"24","author":"Casazza","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib10","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1084\/jem.20151193","article-title":"Tumor macrophages are pivotal constructors of tumor collagenous matrix","volume":"213","author":"Afik","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103060_bib12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in PDAC","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.omtn.2026.103060_bib13","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2018.36.15_suppl.2015","article-title":"Phase 1b\/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma","volume":"36","author":"Colman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib14","doi-asserted-by":"crossref","first-page":"aad3018","DOI":"10.1126\/science.aad3018","article-title":"The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas","volume":"352","author":"Quail","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103060_bib15","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.ymthe.2025.03.024","article-title":"Genetically engineered macrophages reverse the immunosuppressive tumor microenvironment and improve immunotherapeutic efficacy in TNBC","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103060_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/mthe.2000.0027","article-title":"Transduction of Human PBMC-Derived Dendritic Cells and Macrophages by an HIV-1-Based Lentiviral Vector System","volume":"1","author":"Schroers","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103060_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/acs.bioconjchem.7b00768","article-title":"CRISPRed Macrophages for Cell-Based Cancer Immunotherapy","volume":"29","author":"Ray","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2026.103060_bib18","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.001","article-title":"Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy","volume":"325","author":"Shobaki","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103060_bib20","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2026.103060_bib21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103060_bib23","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.103060_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5582\/irdr.2025.01010","article-title":"Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs)","volume":"14","author":"Dou","year":"2025","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.omtn.2026.103060_bib25","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.omtn.2026.103060_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s43018-021-00254-0","article-title":"Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis","volume":"2","author":"Klemm","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib28","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2026.103060_bib30","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.103060_bib31","doi-asserted-by":"crossref","first-page":"eadl5800","DOI":"10.1126\/scitranslmed.adl5800","article-title":"Macrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice","volume":"17","author":"Chen","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.103060_bib33","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","article-title":"Eganelisib, a First-in-Class PI3K\u03b3 Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1\/1b MARIO-1 Trial","volume":"29","author":"Hong","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-17-0357","article-title":"Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals","volume":"24","author":"Shayan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib35","first-page":"4574","article-title":"Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin","volume":"27","author":"Byrne","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib36","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2666","article-title":"A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors","volume":"41","author":"Abdou","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01635-5","article-title":"A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010437","article-title":"Adoptively transferred macrophages for cancer immunotherapy","volume":"13","author":"Park","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib42","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41423-024-01232-z","article-title":"Targeting of TAMs: can we be more clever than cancer cells?","volume":"21","author":"Kzhyshkowska","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib43","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1021\/acs.nanolett.8b00689","article-title":"Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b","volume":"18","author":"Parayath","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2026.103060_bib44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nature10195","article-title":"Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein","volume":"474","author":"Hrecka","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103060_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/0008-5472.CAN-21-1692","article-title":"CRISPR\/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies","volume":"82","author":"Jiang","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103060_bib48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-025-67674-9","article-title":"Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy","volume":"17","author":"Gu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib50","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2026.103060_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.2910260208","article-title":"Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)","volume":"26","author":"Tsuchiya","year":"1980","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib52","article-title":"Comparison of monocytic cell lines U937 and THP-1 as macrophage models for in vitro studies","volume":"32","author":"Nascimento","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.omtn.2026.103060_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00071","article-title":"Convenience versus Biological Significance: Are PMA-Differentiated THP-1 Cells a Reliable Substitute for Blood-Derived Macrophages When Studying in Vitro Polarization?","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2026.103060_bib54","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.176.1.287","article-title":"Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation","volume":"176","author":"Stein","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib57","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib58","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1182\/blood-2012-06-436212","article-title":"Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences","volume":"121","author":"Martinez","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.103060_bib59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103060_bib60","article-title":"Differences between human and rodent nitric oxide production dictate susceptibility to tick-borne Rickettsia","author":"Luu","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2026.103060_bib61","article-title":"Species-specific iNOS expression distinguishes epithelial and myeloid IFN\u03b3 responses in tuberculosis","author":"Stei","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2026.103060_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46237-2","article-title":"IL-4 and IL-13 induce equivalent expression of traditional M2 markers and modulation of reactive oxygen species in human macrophages","volume":"13","author":"Scott","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.103060_bib63","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.4049\/jimmunol.1103426","article-title":"Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models","volume":"188","author":"Lacey","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib64","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.4049\/jimmunol.174.11.6561","article-title":"Arginase-1 and Ym1 Are Markers for Murine, but Not Human, Alternatively Activated Myeloid Cells","volume":"174","author":"Raes","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib65","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1362-4","article-title":"Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment","volume":"18","author":"M\u00fcller","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.omtn.2026.103060_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ady7328","article-title":"Cross-species cellular mapping and humanization of Fc\u03b3 receptors to advance antibody modeling","volume":"11","author":"Van Damme","year":"2026","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212172","article-title":"There is strength in numbers: Quantitation of Fc gamma receptors on murine tissue-resident macrophages","volume":"22","author":"Vorsatz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103060_bib69","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103060_bib70","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib71","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor\u2013engineered T Cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib72","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00262-024-03759-6","article-title":"Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers","volume":"73","author":"Chupradit","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2026.103060_bib73","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple Signaling Roles of CD3\u03b5 and Its Application in CAR-T Cell Therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00789","article-title":"Differential requirements for Src-family kinases in SYK or ZAP70-mediated SLP-76 phosphorylation in lymphocytes","volume":"8","author":"Fasbender","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib76","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib77","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib78","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib79","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib80","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41467-023-37863-5","article-title":"Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting","volume":"14","author":"Ruffo","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib81","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1021\/acssensors.4c01997","article-title":"SynNotch-Programmed Macrophages for Cancerous Cell Detection and Sensing","volume":"9","author":"Wang","year":"2024","journal-title":"ACS Sens."},{"key":"10.1016\/j.omtn.2026.103060_bib82","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/acssynbio.4c00149","article-title":"Engineering an \u03b1CD206-synNotch Receptor: Insights into the Development of Novel Synthetic Receptors","volume":"13","author":"Semeniuk","year":"2024","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.omtn.2026.103060_bib83","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41590-023-01671-2","article-title":"CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity","volume":"24","author":"Tang","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib84","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib85","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1128\/MCB.16.12.6887","article-title":"A Novel Membrane Glycoprotein, SHPS-1, That Binds the SH2-Domain-Containing Protein Tyrosine Phosphatase SHP-2 in Response to Mitogens and Cell Adhesion","volume":"16","author":"Fujioka","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103060_bib86","doi-asserted-by":"crossref","first-page":"E5434","DOI":"10.1073\/pnas.1521069113","article-title":"Cd47-Sirp\u03b1 interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells","volume":"113","author":"Bian","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103060_bib87","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1111\/febs.70192","article-title":"Enhancing macrophage phagocytosis of cancers by disrupting the SIRP\u03b1\/CD47 signaling axis and targeting MUC1 antigen","volume":"292","author":"Muneekaew","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.omtn.2026.103060_bib88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12951-024-02883-w","article-title":"Ultrasound-responsive nanocarriers with siRNA and Fe3O4 regulate macrophage polarization and phagocytosis for augmented non-small cell lung cancer immunotherapy","volume":"22","author":"Li","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2026.103060_bib89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-021-01933-y","article-title":"PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles Downregulate PD-1 Expression by Macrophages and Inhibit Tumor Growth","volume":"22","author":"Hanafy","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.omtn.2026.103060_bib90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2023.12.058","article-title":"Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer","volume":"366","author":"Chen","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103060_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162870","article-title":"SHP2 deneddylation mediates tumor immunosuppression in colon cancer via the CD47\/SIRP\u03b1 axis","volume":"133","author":"Li","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103060_bib92","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.immuni.2020.07.008","article-title":"CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis","volume":"53","author":"Morrissey","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.103060_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib94","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103060_bib95","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12967-025-06469-4","article-title":"PD-1 regulates the anti-tumor immune function of macrophages through JAK2-STAT3 signaling pathway in colorectal cancer tumor microenvironment","volume":"23","author":"Jiang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib96","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103060_bib97","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41590-022-01385-x","article-title":"SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses","volume":"24","author":"Christofides","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib100","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib101","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib102","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302461","article-title":"PD-L1 regulates inflammatory programs of macrophages from human pluripotent stem cells","volume":"7","author":"Cao","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omtn.2026.103060_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.566511","article-title":"Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers","volume":"10","author":"Larionova","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib104","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib105","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1038\/s41388-019-0782-x","article-title":"Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift","volume":"38","author":"Park","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2026.103060_bib106","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8602","article-title":"Lactate supports a metabolic-epigenetic link in macrophage polarization","volume":"7","author":"Noe","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.103060_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41419-022-04632-z","article-title":"Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer","volume":"13","author":"Jiang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2026.103060_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00287","article-title":"Regulations of Glycolytic Activities on Macrophages Functions in Tumor and Infectious Inflammation","volume":"10","author":"Yu","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.omtn.2026.103060_bib109","doi-asserted-by":"crossref","first-page":"13826","DOI":"10.1021\/acsnano.1c05613","article-title":"Sequentially Triggered Bacterial Outer Membrane Vesicles for Macrophage Metabolism Modulation and Tumor Metastasis Suppression","volume":"15","author":"Guo","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103060_bib110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib111","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41467-024-44941-9","article-title":"Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib112","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1021\/acsnano.7b05465","article-title":"Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages","volume":"11","author":"Qian","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2026.103060_bib113","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","article-title":"Remodeling tumor immune microenvironment via targeted blockade of PI3K-\u03b3 and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy","volume":"321","author":"Li","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omtn.2026.103060_bib114","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1002\/adfm.201501283","article-title":"Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi-Peptide Nanoparticles to Tumor-Associated Macrophages and Cancer Cells","volume":"25","author":"Conde","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.omtn.2026.103060_bib115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biomaterials.2018.09.017","article-title":"Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells","volume":"185","author":"Song","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2026.103060_bib116","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/gt.2015.70","article-title":"Strategy of STAT3\u03b2 cell-specific expression in macrophages exhibits antitumor effects on mouse breast cancer","volume":"22","author":"Dang","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2026.103060_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj7002","article-title":"Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity","volume":"8","author":"Kamerkar","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.103060_bib118","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12885-022-09612-2","article-title":"Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer","volume":"22","author":"Glass","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib119","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/acscentsci.9b01235","article-title":"M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKK\u03b2 siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects","volume":"6","author":"Xiao","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.omtn.2026.103060_bib120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib121","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","article-title":"Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2","volume":"72","author":"Duan","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtn.2026.103060_bib122","doi-asserted-by":"crossref","first-page":"913","DOI":"10.4049\/jimmunol.2100230","article-title":"mTORC1 Signaling Regulates Proinflammatory Macrophage Function and Metabolism","volume":"207","author":"Collins","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib123","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.cmet.2016.09.008","article-title":"Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis","volume":"24","author":"Wenes","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.103060_bib124","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.103060_bib125","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/0008-5472.CAN-17-3841","article-title":"Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN\/PI3K\u03b3 to Promote Pancreatic Cancer Metastasis","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib126","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.2A0815-344RR","article-title":"Src family kinase expression and subcellular localization in macrophages: implications for their role in CSF-1-induced macrophage migration","volume":"100","author":"Dwyer","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.omtn.2026.103060_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/501962","article-title":"Macrophage Migration and Its Regulation by CSF-1","volume":"2012","author":"Pixley","year":"2012","journal-title":"Int. J. Cell Biol."},{"key":"10.1016\/j.omtn.2026.103060_bib128","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib129","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omtn.2026.103060_bib130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cmet.2016.06.004","article-title":"Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation","volume":"24","author":"Lampropoulou","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.103060_bib131","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ccell.2024.10.010","article-title":"Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib132","article-title":"Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy","volume":"9","author":"Chen","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2026.103060_bib133","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/or.2022.8282","article-title":"Inhibition of the VEGF signaling pathway attenuates tumor-associated macrophage activity in liver cancer","volume":"47","author":"Okikawa","year":"2022","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omtn.2026.103060_bib134","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2026.103060_bib135","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1096\/fj.201700629R","article-title":"Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer","volume":"32","author":"Binnemars-Postma","year":"2018","journal-title":"FASEB Journal"},{"key":"10.1016\/j.omtn.2026.103060_bib136","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20080108","article-title":"\u201cRe-educating\u201d tumor-associated macrophages by targeting NF-\u03baB","volume":"205","author":"Hagemann","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib137","doi-asserted-by":"crossref","first-page":"E2801","DOI":"10.1073\/pnas.1707929115","article-title":"Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition","volume":"115","author":"Giurisato","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2026.103060_bib138","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12964-020-00557-2","article-title":"Wnt5a-induced M2 polarization of tumor-associated macrophages via IL-10 promotes colorectal cancer progression","volume":"18","author":"Liu","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omtn.2026.103060_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115513","article-title":"Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing","volume":"167","author":"Dong","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omtn.2026.103060_bib140","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41418-023-01194-1","article-title":"TRAF3\/STAT6 axis regulates macrophage polarization and tumor progression","volume":"30","author":"Shi","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omtn.2026.103060_bib141","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4049\/jimmunol.175.2.1197","article-title":"Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK","volume":"175","author":"Hagemann","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib142","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2147\/IJN.S93483","article-title":"Manipulating the NF-& kappa;B pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions","volume":"2163","author":"Ortega","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.omtn.2026.103060_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01383","article-title":"Toll-Like Receptor Ligands and Interferon-\u03b3 Synergize for Induction of Antitumor M1 Macrophages","volume":"8","author":"M\u00fcller","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01650","article-title":"TLR-3 stimulation skews M2 macrophages to M1 through IFN-\u03b1\u03b2 signaling and restricts tumor progression","volume":"9","author":"Vidyarthi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib145","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.103060_bib146","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib147","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1038\/s41467-018-05315-0","article-title":"Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens","volume":"9","author":"Escobar","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib148","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","article-title":"In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases","volume":"41","author":"Kerzel","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omtn.2026.103060_bib149","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2026.103060_bib150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003770","article-title":"Hypoxia-inducible lentiviral gene expression in engineered human macrophages","volume":"10","author":"Chinn","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101204","article-title":"Large-scale generation of IL-12 secreting macrophages from human pluripotent stem cells for cancer therapy","volume":"32","author":"Kang","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.103060_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001202","article-title":"Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma","volume":"8","author":"Gardell","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib153","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/hum.2016.060","article-title":"Genetically Engineered Macrophages: A Potential Platform for Cancer Immunotherapy","volume":"28","author":"Moyes","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.103060_bib154","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3390\/vaccines9111247","article-title":"Alphavirus-Driven Interferon Gamma (IFNg) Expression Inhibits Tumor Growth in Orthotopic 4T1 Breast Cancer Model","volume":"9","author":"Trofimova","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2026.103060_bib155","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.3390\/ijms23137311","article-title":"Interleukin 15 in Cell-Based Cancer Immunotherapy","volume":"23","author":"Zhou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103060_bib156","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.8097338","article-title":"Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages","volume":"260","author":"Hsieh","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.103060_bib157","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4049\/jimmunol.163.5.2902","article-title":"A Novel Function of IL-12p40 as a Chemotactic Molecule for Macrophages","volume":"163","author":"Ha","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib158","first-page":"7853","article-title":"Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model","volume":"63","author":"Satoh","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib159","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4143\/crt.2017.613","article-title":"Tumor-Associated Macrophages Derived TGF-\u03b2\u2012Induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4\/Snail Signaling Pathway","volume":"51","author":"Cai","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.omtn.2026.103060_bib160","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib161","doi-asserted-by":"crossref","DOI":"10.3390\/genes14112033","article-title":"Identification of Niche-Specific Gene Signatures between Malignant Tumor Microenvironments by Integrating Single Cell and Spatial Transcriptomics Data","volume":"14","author":"Saqib","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2026.103060_bib162","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00384-020-03593-z","article-title":"Tumor-associated macrophage infiltration and prognosis in colorectal cancer: systematic review and meta-analysis","volume":"35","author":"Li","year":"2020","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.omtn.2026.103060_bib163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-023-00549-7","article-title":"Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities","volume":"12","author":"Qian","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omtn.2026.103060_bib164","article-title":"PFKFB3 overexpression in monocytes of patients with colon but not rectal cancer programs pro-tumor macrophages and is indicative for higher risk of tumor relapse","volume":"13","author":"Larionova","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310763","article-title":"Establishment and Characterization of Free-Floating 3D Macrophage Programming Model in the Presence of Cancer Cell Spheroids","volume":"24","author":"Korotkaja","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2026.103060_bib166","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1111\/j.1537-2995.2007.01348.x","article-title":"Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation","volume":"47","author":"Khandelwal","year":"2007","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.omtn.2026.103060_bib167","first-page":"333","article-title":"Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome","volume":"19","author":"Guo","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib168","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-21-0986","article-title":"Upregulation of C\/EBP\u03b1 Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer","volume":"27","author":"Hashimoto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1578","article-title":"Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer","volume":"14","author":"Cao","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.omtn.2026.103060_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1486799","article-title":"The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade","volume":"16","author":"Bielski","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib171","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41467-024-49916-4","article-title":"Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome","volume":"15","author":"Guimar\u00e3es","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2026.103060_bib172","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167951","article-title":"Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti\u2013PD-1 resistance","volume":"133","author":"Ajith","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103060_bib173","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184043","article-title":"Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response","volume":"135","author":"Tao","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2026.103060_bib174","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010580","article-title":"Siglec-15 antibody\u2013GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages","volume":"13","author":"Ma","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib175","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2473165","article-title":"MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"14","author":"Llopiz","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.omtn.2026.103060_bib176","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.4049\/jimmunol.1700057","article-title":"Scavenger Receptor MARCO Orchestrates Early Defenses and Contributes to Fungal Containment during Cryptococcal Infection","volume":"198","author":"Xu","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216568","article-title":"Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway","volume":"582","author":"Ding","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omtn.2026.103060_bib178","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/6573891","article-title":"Macrophage Transcriptomic Alterations Driven by Alphavirus-Based Cancer Immunotherapy Vectors","volume":"2025","author":"Korotkaja","year":"2025","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omtn.2026.103060_bib179","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.18632\/aging.202326","article-title":"PTPN2 negatively regulates macrophage inflammation in atherosclerosis","volume":"13","author":"Hu","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.omtn.2026.103060_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1099892","article-title":"The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy","volume":"13","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib181","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006481","article-title":"Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL\/4-1BB co-stimulation","volume":"11","author":"Sun","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omtn.2026.103060_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00117","article-title":"4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity","volume":"5","author":"Bartkowiak","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.103060_bib183","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.4049\/jimmunol.1203194","article-title":"Macrophage Scavenger Receptor A promotes tumour progression in murine models of ovarian and pancreatic cancer","volume":"190","author":"Neyen","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2026.103060_bib184","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-18-2882","article-title":"Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan\u2013Kynurenine\u2013Aryl Hydrocarbon Axis","volume":"25","author":"Labadie","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.103060_bib185","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/CIRCRESAHA.110.216523","article-title":"Control of Macrophage Activation and Function by PPARs","volume":"106","author":"Chawla","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.omtn.2026.103060_bib186","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-023-01680-5","article-title":"Programmable synthetic receptors: the next-generation of cell and gene therapies","volume":"9","author":"Teng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.omtn.2026.103060_bib187","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126002313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:08:26Z","timestamp":1788880106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126002313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":187,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2162253126002313"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103060","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation macrophage engineering in cancer therapy: From TAM reprogramming to CAR-macrophages","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.103060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"103060"}}